Keyphrases
Chemotherapy
100%
Colorectal Cancer
100%
Randomized Trial
100%
Frail Elderly
100%
Comprehensive Geriatric Assessment
28%
Patients with Colorectal Cancer
28%
Reduction Method
28%
Dose Reduction
28%
Number of Patients
28%
Intervention Group
28%
Health Status
14%
Nutrition Status
14%
Improved Survival
14%
Standard of Care
14%
Biological Therapy
14%
Chemotherapy Regimen
14%
Randomized Phase II Trial
14%
Frailty
14%
Multi-domain
14%
Psycho
14%
Geriatrician
14%
Surgical Technique
14%
Herlev
14%
Quality of Life
14%
Cognitive Function
14%
Individual Health
14%
Cancer Mortality
14%
Elderly People
14%
Treatment Delay
14%
Young Patients
14%
International Guidelines
14%
Chemotherapy Toxicity
14%
Health Problems
14%
Recurrence Rate
14%
Elderly Patients
14%
Geriatric Assessment
14%
Ongoing Trials
14%
Vulnerable People
14%
Screening Tool
14%
First Visit
14%
Nutrition Intervention
14%
Comorbidity
14%
Starting Dose
14%
Patients at Risk
14%
Outpatient Clinic
14%
Medicine and Dentistry
Geriatrics
100%
Colorectal Carcinoma
100%
Frail Elderly
100%
Elderly Patient
100%
Geriatric Assessment
60%
Drug Dose Reduction
40%
Surgical Technique
20%
Geriatrician
20%
Frailty
20%
Chemotherapy
20%
Quality of Life
20%
Phase II Trials
20%
Health Status
20%
Side Effect
20%
Therapy Delay
20%
Biological Therapy
20%
Recurrent Disease
20%
Comorbidity
20%
Malignant Neoplasm
20%
Cancer Survival
20%
Functional Status
20%
Nutritional Status
20%
Outpatient
20%
Cognition
20%
Nursing and Health Professions
Elderly Patient
100%
Colorectal Carcinoma
100%
Frail Elderly
100%
Geriatric Assessment
60%
Drug Dose Reduction
40%
Comorbidity
20%
Health Status
20%
Cancer Survival
20%
Surgical Technique
20%
Therapy Delay
20%
Frailty
20%
Side Effect
20%
Functional Status
20%
Quality of Life
20%
Biological Therapy
20%
Recurrent Disease
20%
Malignant Neoplasm
20%
Practice Guideline
20%
Outpatient Department
20%
Nutritional Status
20%
Geriatrician
20%
Health Care Quality
20%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
100%
Chemotherapy
100%
Malignant Neoplasm
22%
Health Status
11%
Frailty
11%
Phase II Trials
11%
Side Effect
11%
Recurrent Disease
11%
Comorbidity
11%
Cancer Survival
11%